Axitinib Pharmacokinetics in Chinese Healthy Volunteers
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
As part of the global clinical development program for AG-013736, studies are ongoing (and
planned) in cancer patients in China. An assessment of AG-013736 pharmacokinetics in Chinese
subjects, as required by the Chinese Health Authorities, is therefore warranted.
In the current study the single dose pharmacokinetics of AG-013736 will be characterized at 3
doses (5 mg, 7 mg and 10 mg).